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Background: The emerging 3q13.31 microdeletion syndrome appears to encompass diverse neurodevelopmental
conditions. However, the 3q13.31 deletion is rare and few adult cases have yet been reported. We examined a
cohort with schizophrenia (n = 459) and adult control subjects (n = 26,826) using high-resolution microarray
technology for deletions and duplications at the 3q13.31 locus.
Results: We report on the extended adult phenotype associated with a 3q13.31 microdeletion in a 41-year-old
male proband with schizophrenia and a nonverbal learning disability. He was noted to have a speech impairment,
delayed motor skills, and other features consistent with the 3q13.31 microdeletion syndrome. The 2.06 Mb deletion
overlapped two microRNAs and seven RefSeq genes, including GAP43, LSAMP, DRD3, and ZBTB20. No overlapping
3q13.31 deletions or duplications were identified in control subjects.
Conclusions: Later-onset conditions like schizophrenia are increasingly associated with rare copy number variations
and associated genomic disorders like the 3q13.31 microdeletion syndrome. Detailed phenotype information across
the lifespan facilitates genotype-phenotype correlations, accurate genetic counselling, and anticipatory care.
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Genomic disorder, Nonverbal learning disabilityBackground
Preliminary evidence suggests that individuals with micro-
deletions at chromosome 3q13.31 (OMIM #615433) may
be predisposed to a broad spectrum of neurodevelopmen-
tal/neuropsychiatric conditions including global develop-
mental delay/intellectual disability (DD/ID), speech delay,
autism spectrum disorder (ASD), and attention deficit
hyperactivity disorder (ADHD) [1-5]. Inconsistent molecu-
lar and cytogenetic techniques as well as variable genomic
breakpoints have made pinpointing the responsible gene(s)
within the 3q13.31 region challenging. In a large case
series, Molin et al. defined a 580 kb shortest region of over-
lap (SRO) that includes five RefSeq genes: DRD3, ZNF80,
TIGIT, MIR568, and ZBTB20 [1]. Those authors proposed
that haploinsufficiency of DRD3 (OMIM #126451), which
codes for the D3 subunit of the dopamine receptor, and
ZBTB20 (OMIM #606025), a DNA transcription repressor
expressed in hippocampal neurons, may contribute to the* Correspondence: anne.bassett@utoronto.ca
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syndrome [1,6]. Recently, a 1.3 Mb deletion at 3q13.31
downstream of this proposed SRO and encompassing just
two genes (LSAMP, GAP43) was identified in a 7-year-old
female with ADHD, hypotonia, and postnatal growth
above the mean [3]. LSAMP (OMIM #603241) en-
codes a limbic system-associated membrane protein
(LAMP) and has been shown to regulate anxiety-like phe-
notypes in mice [7]. GAP43 (OMIM #162060) is almost
exclusively expressed in neuronal tissue and is a candidate
gene for ASD [8].
Later-onset conditions, including neurodevelopmental
diseases like schizophrenia, may also be associated with
rare copy number variations (CNVs) [9]. To date, few
adult cases with 3q13.31 deletions have been described
in the literature, highlighting the paucity of phenotypic
data across the lifespan needed to inform genetic coun-
selling and anticipatory care. Here we provide a descrip-
tion of the extended adult phenotype associated with a
3q13.31 microdeletion [9] that encompasses all four of
the previously proposed neurodevelopmental candidate
genes at this locus: DRD3, ZBTB20, LSAMP, and
GAP43.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Clinical description
The male proband (Figure 1) was conceived naturally
to non-consanguineous parents of European ancestry,
a 29-year-old mother and 36-year-old father. There
was no known family history of major developmental
or neuropsychiatric conditions. The pregnancy and
term delivery were unremarkable; birth weight was
3,941 g (75th-90th percentile). There was no evidence
of hypotonia. The patient was noted to have delayed
motor developmental milestones and “clumsiness”
prior to age 3 years, when he was hospitalized for sus-
pected viral meningoencephalitis with decreased level of
consciousness and dystonic movements. A speech impair-
ment and enuresis was noted thereafter and persisted into
adulthood. At age 9 years, fine motor and perceptual
motor skills were noted to be under-developed. A head
CT (computed tomography) scan at age 15 years showed
focal hypoplasia of the superior cerebellar vermis; a repeat
CT scan at age 33 years was read as normal.
He was enrolled in a special education program begin-
ning at age 7 years, with particular difficulties noted in
mathematics and writing. At age 33 years, clinical neuro-
psychological testing revealed a full-scale IQ in the bor-
derline range. Research-based testing at age 39 years using
the WASI (Wechsler Abbreviated Scale of Intelligence)
demonstrated a full-scale IQ of 75, with a marked differ-
ence between verbal (90) and performance (62) scores
consistent with a nonverbal learning disability.
The patient developed schizophrenia and was first
treated with standard antipsychotic medications at ageFigure 1 Physical features of an adult male with a 3q13.31 microdele
above the mean: at 31 years height was 181.5 cm (75th-90th percentile), we
Findings noted on physical examination as an adult included a broad neck
strabismus, narrow palpebral fissures, a long philtrum, a narrow high arche
had bilateral cubitus valgus, short 4th and 5th metacarpals bilaterally, as we
camptodactyly bilaterally of 4th and 5th toes.24 years. Overall, he has had an unremarkable course of
illness (details available upon request); of note, aggres-
sive behaviour at age 28 years prompted a change in his
medication regimen. His past medical history also in-
cludes type 2 diabetes mellitus treated with insulin and
hypercholesterolemia diagnosed in his 20′s, mild hypo-
calcemia first identified at age 31 years, bilateral L5-S1
disc protrusion requiring surgery at 34 years, and hy-
pertension diagnosed at age 34 years. At time of last
contact, he was 41 years old and living in a supported
situation in the community.
Molecular studies
The patient was recruited into a longitudinal study of
the genetics of schizophrenia [9] at age 31 years. Research
chromosomal microarray analysis using the Affymetrix®
Genome-Wide Human SNP Array 6.0 ultimately demon-
strated a deletion at cytoband 3q13.31 (chr3:115,308,450–
117,370,859, hg18) [9], which was clinically confirmed at a
CLIA (Clinical Laboratory Improvement Amendments)
approved laboratory and reported back to the patient. All
stringent genome-wide CNV calls in this individual are in-
cluded in Additional file 1: Table S1 with only the 3q13.31
deletion predicted to be pathogenic [10]. As is common
with adult-onset disorders like schizophrenia, both parents
were unavailable for testing (deceased). The deletion over-
laps two microRNAs (miRNAs) and seven RefSeq genes
(Figure 2), including the four promising neurodeve-
lopmental gene candidates highlighted by Gimelli et al.
(GAP43 and LSAMP) and Molin et al. (DRD3 and
ZBTB20) [1,3]. The 3q13.31 region was inspected fortion. Anthropometric data demonstrated a post-natal growth pattern
ight was 90.9 kg (BMI 27.6), and OFC was 60.9 cm (97th percentile).
and slight kyphosis. Craniofacial features included facial asymmetry,
d palate, flat occiput, and frontal and occipital hair whorls. He also
ll as narrow feet with mild clinodactyly bilaterally of all toes and
Figure 2 (See legend on next page.)
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Figure 2 3q13.31 deletions and duplications overlapping neuropsychiatric candidate genes DRD3, ZBTB20, LSAMP, and GAP43. The
image was modified from the Database of Genomic Variants (http://dgv.tcag.ca), NCBI Build 36 (hg 18) [13]. Only deletions and duplications
<5 Mb in size and overlapping at least one of DRD3, GAP43, ZBTB20, and LSAMP are shown. Deletions and duplications are represented by red
and blue bars, respectively. All genes (purple) and miRNAs (orange) within the 3q13.2-q13.31 region are shown; splice variants are not included.
The grey bar outlines the coordinates for the 580 kb (chr3:115,335,356-115,916,848) shortest region of overlap (SRO) defined by Molin et al. [1].
The purple bar outlines the boundaries for the Gimelli deletion (chr3:116,640,577- 118,002,810, hg 18) that overlapped GAP43 and LSAMP [3]. The
4.5 Mb deletion reported by Wisniowiecka-Kowalnik [14], the 4.57 Mb deletion in DECIPHER Case 258860, and the 3.4 Mb duplication by Vuillaume
[4] extend beyond the boundary of the figure and are represented by line breaks. Where necessary, all deletion and duplication coordinates
(i.e., excluding the Molin et al. SRO and the case described in this report) were converted from hg 19 to hg 18 using The UCSC Genome LiftOver
tool (http://genome.ucsc.edu).
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database and 10 patients were found to have deletions
overlapping the one presented in this case report (Figure 2)
[11]. In the 26,826 adult control subjects with genome-
wide CNV data available to our colleagues at The
Centre for Applied Genomics (TCAG), no similar
3q13.31 deletions or duplications were identified using
a 50% reciprocal overlap criterion (Additional file 2:
Table S2) [9,12].
Discussion
3q13.31 deletion expression in adults
Including the present case, four adults (≥18 years)
with 3q13.31 microdeletions have been reported in
the literature to date (Table 1) [1,2]. Several features
present in this patient, including DD/ID, speech delay,
enuresis, postnatal growth above the mean, structural
brain abnormalities, high arched palate, and skeletal
anomalies, are consistent with previous reports of
adults with 3q13.31 microdeletions (Table 1) [1,2]. Of
all forty-one cases previously in the literature, the
3q13.31 deletion was reported as occurring de novo
in thirty-eight (92.7%) and of unknown inheritance in
three (7.3%) [1-4,14,15].
Neuropsychiatric phenotypes (i.e., ADHD and ASD)
have been previously associated with the 3q13.31 micro-
deletion; however, this is the first report of schizophrenia
in an individual with a 3q13.31 microdeletion. Moreover,
the patient described in this report had a >25 point dis-
crepancy between his performance and verbal IQ scores,
consistent with a nonverbal learning disability [16].
Interestingly, the 42 year old female (Case 6) reported in
Shuvarikov et al. [2] demonstrated a similar trend in IQ
scores (Table 1). Raw IQ scores were not given for many
of the paediatric cases, however Vuillaume et al. [4]
described an affected 16 year old female (Case 1) as “being
able to read and write but educational learning was
difficult,” potentially describing a nonverbal learning
disability. Detailed neuropsychological phenotyping of
additional cases will help determine if nonverbal
learning disabilities are part of the emerging 3q13.31
microdeletion syndrome.Candidate genes for neuropsychiatric expression
The four genes (GAP43, DRD3, LSAMP, and ZBTB20)
that have been posited as contributing to the brain
phenotype of the 3q13.31 microdeletion syndrome are
all overlapped by this patient's deletion (Figure 2) [1,2].
Regarding these genes and their potential role in schizo-
phrenia and related neuropsychiatric conditions, non-
synonymous point mutations in GAP43 were recently
identified in two unrelated schizophrenia cases in a
next-generation sequencing study [17]. DRD3 has been a
longstanding candidate gene for schizophrenia, largely
based on its affinity to bind antipsychotic drugs and its
localization in limbic brain structures [18]. Further,
LSAMP and ZBTB20 have each been implicated in vari-
ous brain regions associated with schizophrenia. In a
post-mortem study of schizophrenia, LSAMP expression
was noted to be increased by ~20% in the dorsolateral
prefrontal cortex of individuals with schizophrenia com-
pared to controls [19]. In mice, ZBTB20 knockdowns
were noted to have faulty hippocampal cytoarchitecture
and selective ablation of ZBTB20 in mature hippo-
campal CA1 neurons led to disruptions in learning
and memory [20,21].
In addition to genic haploinsufficiency, other molecu-
lar mechanisms may contribute to the phenotype of the
3q13.31 microdeletion syndrome. In particular, recent
reports suggest miRNAs may play a role in mediating
the risk for neurodevelopmental disorders [22,23]. Both
miRNAs overlapped by the 3q13.31 deletion in this
patient (miR-4796, miR-568) have predicted targets that
are additional candidate genes for schizophrenia and
related disorders, including SHANK2 and FMR1 [24,25].
The individual and collective influence of the above
mentioned genes and miRNAs on the neuropsychiatric
expression of the 3q13.31 microdeletion is deserving of
further study. Of interest with respect to genotype-
phenotype correlations are the few reports to date of the
reciprocal 3q13.31 duplication, in which individuals
appear to share some (i.e., DD/ID, hypotonia) but not all
of the same clinical features as the 3q13.31 microdeletion
[4,26]. The fact that neither deletions nor duplications at
3q13.31 were identified in 26,826 controls suggest that
Table 1 Clinical features of four adults with 3q13.31 deletions






Age (years) 41 19.5 18 42
Sex Male Male Male Female
Ethnicity European NR NR NR
OFC (percentile) 97th 90th 97th 50-75th
Height
(percentile)
75th-90th 95th 99th 10-25th
Weight
(category)
Overweight NR NR Obese
Neurocognitive Borderline intellectual
disability (VIQ 90, PIQ 62)




(VIQ 94, PIQ 61)






Social and emotional immaturity
Neurologic Delayed motor development,
focal hypoplasia of the superior
cerebellar vermis (15 y), enuresis
Hypotonia Hypotonia Cerebellar agenesis, EEG
abnormalities, hypotonia, enuresis
Musculoskeletal Bilateral L5-S1 disc protrusion,
slight kyphosis
Kyphosis NR NR
Genitalia NA Small testes (8 ml) Normal Small introitus
Craniofacial Broad neck, facial asymmetry,
strabismus, narrow palpebral
fissures, long philtrum, narrow high
arched palate, flat occiput, frontal
and occipital hair whorls (Figure 1)
Dolichocephaly, prominent broad
forehead, strabismus, myopia,
ptosis, antimongoloid slant, short
philtrum, high arched palate, large






Absent eyebrows, epicanthal folds,
down slanting palpebral fissures,
ptosis, high palate, nystagmus,
microstomia, small teeth,
large palatine tori
Hands and feet Cubitus valgus, bilateral short 4th
and 5th metacarpals, narrow feet
with mild bilateral clinodactyly and
camptodactyly of toes




Uneventful pregnancy, birth weight
3941 g (75th-90th percentile)




Other Insulin dependent Type 2 diabetes
mellitus, hypercholesterolemia,
hypocalcemia, hypertension
NR NR Large angioma in right shoulder,
dorsocervical fat pad
OFC, occipital frontal circumference; NR, not reported; NA, not assessed; FSIQ, full scale intelligence quotient; VIQ, verbal intelligence quotient; PIQ, performance
intelligence quotient; ADHD, attention deficit hyperactivity disorder; EEG, electroencephalography. Square brackets used to highlight ascertainment feature.
Lowther et al. Molecular Cytogenetics 2014, 7:23 Page 5 of 7
http://www.molecularcytogenetics.org/content/7/1/23copy number aberrations in this region, rather than hap-
loinsufficiency alone, may be associated with the deleteri-
ous phenotypic consequences.
Implications for clinical practice
Cytogenetic anomalies may be found in up to 5-8% of
cases with schizophrenia, suggesting a potential future
role for clinical microarray testing in this population [9].
The occurrence of schizophrenia in the patient reported
here could be unrelated to the 3q13.31 microdeletion.
However, multiple lines of evidence, including the variable
expression of many other recurrent large, rare CNVs,
suggest a genetically-related neuropsychiatric spectrum of
disease that includes both DD/ID and schizophrenia
[9,27,28]. This is, to our knowledge, the first report of a3q13.31 deletion discovered in a schizophrenia cohort.
This attests to the overall rarity of these variants, and to
the relative paucity of available data (almost all of which
are research-based) compared with diseases like DD/ID
where clinical microarray testing is now the first-tier diag-
nostic test [9,29]. More data are needed to delineate the
role of pathogenic CNVs in the dual-diagnosis (schizophre-
nia and premorbid ID) population to which this patient
would belong, where the yield may be significantly higher
and where clinical testing is already indicated [30].
Conclusions
In conclusion, we have identified an adult male with
schizophrenia and a 3q13.31 deletion overlapping four
promising neurodevelopmental candidate genes: DRD3,
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like schizophrenia are increasingly associated with rare
CNVs. Detailed phenotypic information across the lifespan
facilitates genotype-phenotype correlations, accurate gen-
etic counselling, and anticipatory care.
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